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Abstract: Hereditary Inclusion Body Myopathy (HIBM2) is a chronic progressive skeletal muscle wasting disorder which 
generally leads to complete disability before the age of 50 years. There is currently no effective therapeutic treatment for 
HIBM2. Development of this disease is related to expression in family members of an autosomal recessive mutation of the 
GNE gene, which encodes the bifunctional enzyme UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE/MNK). This is the 
rate limiting bifunctional enzyme that catalyzes the ﬁ  rst 2 steps of sialic acid biosynthesis. Decreased sialic acid production, 
consequently leads to decreased sialyation of a variety of glycoproteins including the critical muscle protein alpha-dystroglycan 
(α-DG). This in turn severely cripples muscle function and leads to the onset of the syndrome. We hypothesize that replac-
ing the mutated GNE gene with the wildtype gene may restore functional capacity of GNE/MNK and therefore production 
of sialic acid, allowing for improvement in muscle function and/or delay in rate of muscle deterioration. We have constructed 
three GNE gene/CMV promoter plasmids (encoding the wildtype, HIBM2, and Sialuria forms of GNE) and demonstrated 
enhanced GNE gene activity following delivery to GNE-deﬁ  cient CHO-Lec3 cells. GNE/MNK enzyme function was sig-
niﬁ  cantly increased and subsequent induction of sialic acid production was demonstrated after transfection into Lec3 cells 
with the wild type or R266Q mutant GNE vector. These data form the foundation for future preclinical and clinical studies 
for GNE gene transfer to treat HIBM2 patients.
Introduction
Hereditary Inclusion Body Myopathy 2 (HIBM2) is an autosomal recessive muscle wasting syndrome 
with its onset between the ages of 20 and 40 years of age progressing to severe incapacitation within 5 to 
15 years (Argov and Yarom, 1984). Etiology for this disorder is based on the presence of mutations of 
the GNE gene. Worldwide an estimated 271 cases are reported, 159 in the Middle East (Iranian-Jewish 
heritage) which bear the M712T founder mutation and 42 are reported to have the V572L founder muta-
tion, identiﬁ  ed in the Japanese population (see http://hibm.org/hrg/pages/research-services/gne/ibm2-
mutations.php). GNE is a highly conserved gene identiﬁ  ed as 1 of 40 genes exclusively shared by 
vertebrates and bacteria (Salzberg, White et al. 2001). It encodes the bifunctional enzyme uridine diphos-
phate-N-acetylglucosamine 2—epimerase/N-acetylmannosamine kinase (GNE/MNK) which catalyzes 
the ﬁ  rst two sequential sialic acid pathway reactions critical to sialic acid synthesis, and HIBM2 mutations 
are distributed over the whole enzyme (Argov, Eisenberg et al. 2003; Krause, Schlotter-Weigel et al. 
2003; Broccolini, Ricci et al. 2004; Huizing, Rakocevic et al. 2004; Saito, Tomimitsu et al. 2004).
Sialic acid is the only monosaccharide of glycoconjugates that bears a net negative charge (Alberts, 
Bray et al. c1994). This charged sugar provides the terminal carbohydrate on a variety of N-linked and 
O-linked glycoproteins that mediate cell-cell and protein-protein interactions. The sialic acid modiﬁ  ca-
tions of cell surface glycoproteins are crucial for cell adhesion and signal transduction and may result 
in muscle ﬁ  ber degeneration (Huizing, Hermos et al. 2002; Vasconcelos, Raju et al. 2002). Although 
sialic acid dysregulation is likely to signiﬁ  cantly contribute to disease pathogenesis, recent assessments 
of myoblast cellular sialylation patterns suggest the possible role of other GNE related contributing 
mechanisms, such as GM3 and GD3 synthase regulation and impaired apoptosis signalling (Hinderlich, 244
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Salama et al. 2004; Salama, Hinderlich et al. 2005; 
Wang, Sun et al. 2006; Amsili, Shlomai et al. 
2007). Additionally, recent developments in the 
ﬁ  eld of GNE research has implicated the bifunc-
tional enzyme to also play a role in functions other 
than sialic acid production. These functions 
include cell proliferation, apoptosis, regulatory 
gene expression and modulatory sialytransferases 
(Wang, Sun et al. 2006; Amsili, Shlomai et al. 
2007).
There is no current effective treatment for 
HIBM2, unlike the related disorders of inﬂ  amma-
tory myopathies (polymyositis and dermatomyo-
sitis) that respond somewhat to corticosteroids, 
plasmaphoresis/ﬁ  ltration (removal of immuno-
genic proteins) or other immunosuppressive 
therapies (Dalakas, 1991; Oldfors and Lindberg, 
1999). In an initial double-blind, placebo-controlled 
trial involving 19 individuals utilizing immuno-
globulins (IVIg) as treatment for sporadic IBM, no 
statistically significant beneficial effects were 
observed (Dalakas, Sonies et al. 1997). Similar 
results were demonstrated in a more recent study 
involving 4 patients with HIBM2 treated with IVIg 
containing 8 μmoles sialic acid per gram (Sparks, 
Rakocevic et al. 2007). Even though some 
improvement in muscle function with variable and 
transient clinical improvement with daily activities 
was observed, no objective evidence of improved 
muscle sialylation at post treatment muscle biopsy 
was demonstrated (Sparks, Rakocevic et al. 2007). 
A third study involving 36 patients with sporadic 
IBM in which IVIg was combined with prednisone 
also demonstrated no effectiveness in improving 
muscle function (Dalakas, Koffman et al. 2001).
We hypothesize a novel therapeutic opportunity 
for HIBM2 using a newly constructed wildtype 
GNE gene plasmid thereby addressing both sialic 
acid based and alternative GNE-based mechanisms 
of cellular dysfunction and have demonstrated 
GNE transgene expression along with sialic pro-
duction in GNE defective CHO-Lec 3 cells.
Materials and Methods
GNE cloning
Parental vectors containing the GNE cDNA were 
provided by Daniel Darvish (HIBM Research 
Group; Encino, CA) and included pGNE-NB8 
(wild type), pGNE-MB18 (M712T mutant), and 
pGNE-R266Q (R266Q mutant). The destination 
vector, pUMVC3, was purchased from Aldevron 
(Fargo, ND). The subcloning vector, pDrive 
(Qiagen; Valencia, CA), was used to shuttle the 
R266Q mutant from the parent vector to the des-
tination vector.
Wild type and M712T GNE was cloned from the 
parent vector into pUMVC3 via Eco RI restriction 
digest, gel puriﬁ  cation, and T4 ligation. The R266Q 
mutant GNE was cloned from the parent vector into 
pDrive via Hind III + Xba I digest and then moved 
to pUMVC3 via Sal I + Xba I. (Fig. 1) All 
pUMVC3-GNE clones were sequenced by Seqwright 
(Houston, TX) with the following primers: GNE-F1, 
5'-TGTGAGG  ACCATGATCGCATCCTT-3'; GNE-F2, 
5'-ACCTCCGAGTTGCAATAGTCAGCA-3'; GNE-
R1, 5'-AATCAGGCCCATCCAGAGACACAA-3'; 
GNE-R2, 5'-TTCCAATCTGACG TGTTCCCAGGT-
3'; UMVC-F, 5'-CGCCACCAGACATAATAGCT-
GACA-3'; and UMVC-R, 5'-TAGCCAGA 
AGTCAGATGCTCAAGG-3'. Positive pUMVC3-
GNE clones were grown overnight in 175mls LB 
broth + 50 ug/ml Kan and 150 mls culture was 
used for the Qiagen (Valencia, CA) HiSpeed 
Plasmid Maxi kit according to the manufacturer 
protocols.
Cell culture
GNE deﬁ  cient CHO-Lec3 cells were provided by 
Pamela Stanley at Albert Einstein College of 
Medicine (Hong and Stanley, 2003). The cells 
were grown at 37 °C in 5% CO2 in alpha-MEM 
media supplemented with 4mM L-glutamine and 
10% heat inactivated, Fetal Bovine Serum. Cells 
for transient transfections were plated at 1 × 10^6 
cells per well in 6-well plates and grown over-
night. Lec3 cells were weaned to reduced serum 
conditions by reducing the FBS by 2.5% per 
passage.
Transient transfections
Lec3 cells were transfected for 6 hours with DNA:
lipid complex per well in OptiMEM (Invitrogen; 
Carlsbad CA), then the media was changed to 
normal alpha-MEM growth media and the cells 
were cultured overnight. DNA:lipid complexes 
were formed by mixing 4 ug DNA + 10 ul Lipo-
fectamine 2000 (Invitrogen) according to the 
manufacturers protocol. Twenty-four hours post 
transfection, cells were harvested by trypsin digest 
and washed once with PBS before subsequent 
western blot or enzyme/sugar assays.245
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mRNA quantitation
Total RNA was extracted from 1.5 million trans-
fected CHO-Lec3 cells using the RNeasy kit 
according to the manufacturers instructions 
(Qiagen, Valencia, CA). The puriﬁ  ed RNA was 
quantiﬁ  ed by 260/280 ratio using the NanoDrop1000 
spectrophotometer (NanoDrop, Wilmington, 
DE). Five hundred nanograms of total RNA was 
converted to cDNA using oligo dT primers and 
the TaqMan reverse transcription kit (ABI, Foster 
City, CA). Using the Sybr Green PCR master mix 
(ABI, Foster City, CA) along with 25 ng cDNA and 
0.2 pM primers (GNE-F3 = 5'-cggaagaagggcatt-
gagcatc-3' and GNE-R3 = 5'-tttgtcttgggtgtcag-
catcc-3'), 25 ul PCR reactions were compared 
against serial dilutions of a known concentration 
of pUMVC3-GNE-wt DNA. The Sybr Green 
ﬂ  uorescence was detected using the iQ5 real time 
PCR detection system (BioRad, Hercules, CA) 
and the PCR conditions: 95 °C–10 min to activate 
the enzyme and (95 °C–15 sec and 58 °C–60 sec) × 
45 cycles to amplify the product. Fifteen 
microliters of the PCR reaction was run on a 
4% pre-cast agarose E-gel (Invitrogen, Carlsbad, 
CA) and the image was captured using the 
G-box chemiluminescence detection system 
(Frederick, MD).
Western blot
Approximately 5 × 10^5 cells were used for west-
ern blot analysis. Cell pellets were lysed using 20 ul 
Cell lytic (Sigma; St. Louis, MO) plus 1% protease 
inhibitors. The cell debris was spun down at 
maximum speed for 5 minutes and the supernatant 
was mixed 1:1 with Laemmli buffer (BioRad; 
Hercules, CA) containing 5% β-ME. Protein 
samples were separated by polyacrylamide 
electrophoresis at 100V for 2 hours on 10% 
denaturing gels, followed by transfer to PVDF 
membrane using 100 volts for 2 hours. The 
membranes were probed for GNE and GapDH 
using chicken anti-GNE (1:10,000 dilution) and 
mouse anti-GapDH (1:50,000 dilution) overnight. 
Primary antibodies were detected using HRP-
labeled secondary antibodies and they were visual-
ized using the West Dura detection reagent 
GNE inserts:
•WT
￿M712T mut
￿R266Q mut
Figure 1. pUMVC3-GNE expression vector.246
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(Pierce; Rockford, IL) and the G-box chemilumi-
nescence camera (Syngene; Frederick, MD).
Sialic acid quantitation
Approximately 4 × 10^6 cells were used for the 
quantiﬁ  cation of membrane-bound sialic acid by 
the thiobarbituric acid method. Cells were resus-
pended in water and lysed by passage through a 
25 gauge needle 20 times and centrifuged. The 
supernatant was used for Bradford protein estima-
tion and the remaining pellet was resuspended in 
100 μl 2 M acetic acid and incubated 1 h at 80 °C 
to release glycoconjugate-bound sialic acids. 
137 μl of periodic acid solution (2.5 mg/ml in 
57 mM H2SO4) were added and incubated for 
15 min at 37 °C. Then 50 μl of sodium arsenite 
solution (25 mg/ml in 0.5 M HCl) were added and 
the tubes were shaken vigorously to ensure com-
plete elimination of the yellow-brown color. After 
this step 100 μl of 2-thiobarbituric acid solution 
(71 mg/ml adjusted to pH 9.0 with NaOH) were 
added and the samples were heated to 100 °C for 
7.5 min. The solution was extracted with 1 ml of 
butanol/5% 12 M HCl and the phases were sepa-
rated by centrifugation. The absorbance of the 
organic phase was measured at 549 nm. The 
amount of sialic acids was given as nmol sialic 
acid/mg of protein.
Kinase and epimerase activity
UDP-GlcNAc 2-epimerase activity was deter-
mined by a colorimetric assay (Blume, Chen et al. 
2002). It contained 45 mM Na2HPO4, pH 7.5, 
10 mM MgCl2, 1 mM UDP-GlcNAc and variable 
amounts of protein in a ﬁ  nal volume of 200 μl. The 
reaction was performed at 37 °C for 30 min and 
stopped by boiling for 1 min. The released Man-
NAc was detected by the Morgan-Elson method 
(Reissig, Storminger et al. 1955). In brief, 150 μl 
of sample were mixed with 30 μl of 0.8 M H2BO3, 
pH 9.1, and boiled for 3 min. Then 800 μl of 
DMAB solution (1% (w/v) 4-dimethylamino 
benzaldehyde in acetic acid/1.25% 10 N HCl) was 
added and incubated at 37 °C for 30 min. The 
absorbance was read at 578 nm.
ManNAc kinase activity was measured by a 
radiometric assay (Hinderlich, Stasche et al. 1997). 
It contained 60 mM Tris/HCl, pH 8.1, 10 mM 
MgCl2, 5 mM ManNAc, 50 nCi [14C]ManNAc, 
10 mM ATP, and variable amounts of protein in a 
ﬁ  nal volume of 200 μl. The reaction was performed 
at 37 °C for 30 min and stopped by addition of 
300 μl of ethanol. Radiolabeled compounds were 
separated by paper chromatography and radioac-
tivity was determined by liquid scintillation 
counting.
Statistical analysis
Independent experiments for enzyme activity 
and sialic acid expression were performed. The 
student’s t-test was used to determine p-values 
for each treated group, relative to the untreated 
sample. One way analysis of variance (ANOVA), 
followed by Duncan’s multiple comparisons 
test when appropriate, was used to determine 
p values for each treated group, relative to each 
other.
Results
Creating GNE clones
GNE cDNA clones tested included a human wild 
type cDNA and two human mutant cDNAs. The 
mutants included the M712T GNE deﬁ  cient clone 
and the R266Q sialuria clone. Sialuria is a human 
disease caused by point mutations in the CMP-
sialic acid binding site of GNE, leading to a loss 
of feed-back inhibition and mass production of 
sialic acids. GNE cDNAs were subcloned from 
their original vectors to the expression vector, 
pUMVC3 by restriction digest cloning. Clones 
were screened by directional restriction enzyme 
digest to conﬁ  rm the GNE insert was in the correct 
orientation. (data not shown) Positive clones were 
sequenced in both orientations to conﬁ  rm no muta-
tions occurred during the cloning process. The 
resulting chromatograms were compared against 
the GNE sequence from GenBank (accession # 
NM_005467) and the wild type had no mutations, 
whilst the M712T and R266Q clones contained 
only the expected point mutations (Sup Fig. 1). 
Positive pUMVC3-GNE clones were scaled up by 
maxi prep plasmid puriﬁ  cation and sequenced 
again to conﬁ  rm no mutations occurred (data not 
shown). These DNA stocks were used for all sub-
sequent experiments.
Gene protein expression
Plasmid UMVC3-GNE DNA was transiently trans-
fected into CHO-Lec3 cells and grown in 10% 247
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serum for 24 hours, and then the cells were 
harvested and analyzed for recombinant GNE 
expression. The GNE western blot illustrates that 
the untreated Lec3 cells do not express GNE and 
CHO-Lec3 cells transfected with different 
pUMVC3 clones express high levels of recombi-
nant GNE (Fig. 2). The expression level is relatively 
equivalent, regardless of GNE isoform. In a second 
experiment recombinant GNE was expressed fol-
lowing transfection of CHO-Lec3 cells grown in 
10% or 2.5% fetal bovine serum (FBS), due to the 
ability of CHO cells to incorporate sialic acids from 
the culture media (see sialic acid quantiﬁ  cation 
below). Again, GNE protein expression was rela-
tively equivalent, regardless of GNE isoform and 
the concentration of FBS (Fig. 3).
Wt-GNE mRNA quantitation
CHO-Lec3 cells were grown in 10% serum and 
transiently transfected with pUMVC3-GNE-wt 
DNA for 24 h to quantitate the amount of recom-
binant GNE RNA was expressed. Total RNA was 
extracted and RT- QPCR was performed to amplify 
a 230 bp fragment from the GNE transcript. Serial 
dilutions of pUMVC3-GNE-wt were used to deter-
mine that the concentration of GNE-wt expressed 
in transfected Lec3 cells was equal to 4.1 pg/ul. 
The dynamic range of the QPCR was from 5ng–5fg 
and there was no GNE mRNA product detected in 
control (untransfected) CHO-Lec3 cells (the cT 
value for untransfected cells was greater than 
42 cycles, which is less than 5fg). Therefore, we 
were able to detect recombinant GNE mRNA 
expression in transfected Lec3 cells, while 
untransfected cells had undetectable amounts of 
GNE mRNA. (Fig. 4).
GNE enzyme assays
In addition to the western blot assay, an aliquot of 
the transfected cell pellets were assayed for enzyme 
activity. Both epimerase and kinase activity were 
quantiﬁ  ed in Lec3 cells with or without recombi-
nant GNE protein (Table 1). Lec3 cells alone had 
both epimerase and kinase activities less than 
3 mU/mg, which displays background activity. 
Cells expressing wild type, M712T, or R266Q GNE 
had an average of 22, 31, and 26 mU/mg of epim-
erase activity, respectively. The same Lec3 samples 
displayed an average of 35, 32, and 38 mU/mg of 
kinase activity. All of the cells expressing recom-
binant GNE had enzyme activity signiﬁ  cantly 
above the non-treated cells with a p-value ≤ 0.008 
for both epimerase and kinase activities. Using 
one-way ANOVA, followed by Duncan’s multiple 
comparison, there was no statistical difference in 
enzyme activity between the three different GNE 
isoforms, with p-values greater than 0.05.
Sialic acid assays
Transfected Lec3 cells also were tested for cell 
surface sialic acid expression. All Lec3 samples 
had approximately 6.0 nmol/mg membrane bound 
sialic acid, with the exception of Lec3 cells trans-
fected with the R266Q GNE, which had a 1.5-fold 
higher amount. The R266Q mutant lacks the feed-
back inhibition of GNE and is known to cause an 
overproduction of intracellular sialic acids. Lec3 
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Figure 2. GNE expression in CHO-Lec3 cells grown in 10% serum. 
Lane 1: untreated Lec3 cells. Lane 2: wt GNE. Lane 3: M712T GNE. 
Lane 4: R266Q GNE.
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Figure 3. GNE expression in CHO-Lec3 cell lines. Lanes 1–4: CHO-
Lec3 cells grown in 10% FBS. Lanes 5–8: CHO-Lec3 cells grown in 
2.5% FBS. Lanes 1 and 5: Untreated Lec3 cells. Lanes 2 and 6: wt 
GNE. Lanes 3 and 7: M712T GNE. Lanes 4 and 8: R266Q GNE.248
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cells seem to be undersialylated, and this could 
only be overcome by expression of the sialuria 
mutant and not by the about 100-fold overexpres-
sion of wild-type GNE compared to wild-type 
CHO cells.
No differences between wt and M712T GNE 
were observed. This was likely due to the incorpo-
ration of sialic acids from the cell culture medium, 
as it is known that sialic acids from FBS can bypass 
the defective GNE pathway (Hong and Stanley, 
2003; Hinderlich, Salama et al. 2004). In this case 
differences between wt and M712T could be 
masked by the bypass. We therefore altered the cell 
culture conditions by reducing the percent serum 
(FBS) in the media. As the serum level was reduced, 
sialic acid production decreased, with a marked 
decrease demonstrated at 2.5% FBS (Table 2). 
Sialic acid levels continued to decrease as the cell 
culture media approached serum free conditions, 
but the cell morphology and growth characteristics 
were altered (data not shown). It was determined 
that the 2.5% FBS concentration of the cell culture 
media was optimal in order to test the impact of 
GNE gene transfection in Lec3 cells.
Lec3 cells were thus grown in 2.5% FBS and 
transfected with pUMVC3-GNE clones. GNE 
expression was concurrently conﬁ  rmed via western 
blot (Fig. 3). Signiﬁ  cant increase of sialic acid 
production was indeed demonstrated, again with 
the best effect of the R226Q mutant (Fig. 5, 
p = 0.0157 for GNE-wt; p = 0.0566 for GNE 
R266Q). A slight, but significant difference 
between wt and M712T GNE was observed, indi-
cating, that the re-sialylation capability of the 
mutant is lower than that of the wild-type, likely 
hinting at a similar mechanism in HIBM muscle.
Discussion
We created several GNE expression vectors from 
human cDNA. Three different GNE forms, wild 
type, M712T, and R266Q, were robustly expressed 
in GNE deﬁ  cient cells (Lec3 cells). All enzymes 
demonstrated similar protein expression levels, 
albeit distinct enzymatic activities. The transfected 
GNE expressing cell lines produced signiﬁ  cantly 
more sialic acid than untransfected cells.
Studies on HIBM2 reveal mutations in the GNE 
gene associated with glycosylation errors in the 
muscle membrane which may lead to defective 
muscle function. Loss of GNE activity in HIBM2 
is thought to impair sialic acid production and 
interfere with proper sialylation of glycoconjugates 
(Huizing, Rakocevic et al. 2004; Saito, Tomimitsu 
et al. 2004). The reactivities to lectins are also 
variable in some myofibers, suggesting that 
hyposialylation and abnormal glycosylation in 
muscles may contribute to the focal accumulations 
0
.
5
n
g
 
G
N
E
0
.
0
0
5
n
g
 
G
N
E
0
.
0
0
0
0
5
n
g
 
G
N
E
0
.
0
0
0
0
0
0
5
n
g
 
G
N
E
C
H
O
+
G
N
E
-
w
t
C
H
O
 
c
e
l
l
s
 
o
n
l
y
-
w
t
1      2      3      4       5       6
Figure 4. GNE mRNA is expressed in transfected CHO-Lec3 cells, 
but not in control cells. Lanes 1–4 contain 15 ul of serial diluted 
pUMVC3-GNE-wt PCR product, which was used to quantitate the 
amount of GNE mRNA present in the Lec3 samples. Lanes 5–6 
contain 15 ul of the PCR product from transfected or untransfected 
Lec3 cells.
Table 1. GNE enzyme activity of CHO Lec3 cells transfected with different plasmids.
Lec3 cells+DNA Epimerase act
(mU/mg)
p-value Kinase act
(mU/mg)
p-value
Untreated 1 ± 0.7 2 ± 1.4
WT GNE 22 ± 0.6 0.001* 35 ± 0.7 0.001*
M712T GNE 31 ± 1.4 0.001* 32 ± 2.1 0.003*
R266Q GNE 26 ± 2.9 0.007* 38 ± 4.2 0.008*
*comparison to untreated.249
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of autophagic vacuoles and/or amyloid deposits in 
affected patient muscle tissue.
Sialic acids can be found as part of cell surface 
glycoproteins, glycolipids, gangliosides, and poly-
saccharides and form a large part of the glycocalyx 
which plays a large role in the function of the cell 
membrane. The activity of the enzyme necessary for 
sialic acid production can be controlled at the tran-
scriptional level (Oetke, Hinderlich et al. 2003). The 
negative charge of the cell surface is ascribed to sialic 
acid with an afﬁ  nity for various cations, particularly 
calcium (Ca
++). The glycocalyx on the cell surface 
blends with the ground substance of the interstitial 
space and abuts the basement membrane of closely 
applied capillaries (Frank and Langer, 1974). This 
relationship provides for a signiﬁ  cant amount of 
capillary-cellular exchange. Experimental observa-
tion reveals a signiﬁ  cant variability in muscle con-
tractile force based on Ca
++ availably, when artiﬁ  cially 
altered in the vascular supply (Shine, Serena et al. 
1971). The bound Ca
++ in the glycocalyx appears to 
be in rapid equilibrium with Ca
++ in the vascular and 
interstitial spaces and is the probable immediate 
source of the Ca
++ that crosses the sarcolemma. The 
Ca
++ bound at the surface also seems to be important 
in the excitation-contraction (EC) coupling sequence, 
whether as a source of "trigger" Ca
++ for the sarco-
tubular system or as a direct activator of the myo-
ﬁ  laments. The integrity of the sialic acid component 
of the glycocalyx appears to be necessary for the 
binding of Ca
++ and for the prevention of uncon-
trolled Ca
++ entry into the cell allowing for effective 
muscle contraction (Langer, 1978).
Attempts to palliate HIBM2 progression with 
Sialic Acid, ManNAc or saliated protein replace-
ment, which bypass the defective epimerase and/or 
kinase related to the GNE mutation, are being 
Table 2. Sialic acid levels of CHO Lec3 cells cultivated 
in different concentrations of FBS.
% FBS Sialic acid (nmol/mg) p-value
10 8.05 ± 0.27
5.0 7.26 ± 0.61 0.2996*
2.5 4.69 ± 1.20 0.0096*
*comparison to 10% FBS.
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Figure 5. Sialic acid is reconstituting by GNE expression in CHO-Lec3 cells cultivated in the presence of 2.5% FBS. In comparison to 
untreated Lec3 cells, sialic acid production was signiﬁ  cant greater following GNE-wt (p = 0.0157) transfection. GNE-R266Q (p = 0.0566) and 
GNE-M712T (p = 0.0708) approached signiﬁ  cance.250
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explored in various experimental trials. Supportive 
preliminary preclinical results suggest potential 
improvement in function of GNE mutated ﬁ  bro-
blasts (Huizing, Hermos et al. 2002). A novel 
homozygous mutant (GNE
M712T/M712T) mouse 
model which does not develop myopathy but does 
develop early renal failure and death related to 
kidney dysfunction was shown to have transient 
improvement in survival following treatment with 
ManNA protein. These mice unfortunately do not 
demonstrate the functional myopathic abnormali-
ties associated with HIBM2. HIBM2 patients do 
not have associated renal dysfunction, and thus this 
model is of limited use for evaluation of clinical 
product testing (Galeano, Klootwijk et al. 2007; 
Quaggin, 2007). Some groups have tried to create 
a GNE deﬁ  cient mouse model containing myo-
pathic related characteristics, but the homozygous 
mutants die in utero (Schwarzkopf, Knobeloch 
et al. 2002; Malicdan, Noguchi et al. 2007). 
However, the M712T mouse model may help point 
to possible therapies which ultimately will require 
rigorous clinical validation. GNE-null mice bearing 
the D176 GNE human transgene do show myopa-
thy reminiscent of HIBM2 after 10 months of age 
(Malicdan, Noguchi et al. 2007), however the 
molecular basis of myopathy in this model remains 
controversial since the muscle GNE expression is 
higher than expected physiologic levels. Addition-
ally, due to multi-organ problems and unpredict-
able survival, the utility of this mouse model for 
pre-clinical trials remain suboptimal. We investi-
gated the effect of a novel GNE gene/CMV pro-
moter plasmid for mRNA and protein expression 
in GNE deﬁ  cient CHO-Lec 3 cells and were able 
to restore GNE/MNK enzyme function and subse-
quent induction of sialic acid production.
Preclinical studies with myogenic stem cells 
have failed to show functional improvement in 
muscle function (Partridge, Morgan et al. 1989; 
Barr and Leiden, 1991; Dhawan, Pan et al. 1991; 
Mendell, Kissel et al. 1995). Development of a 
relevant mouse model would facilitate the pre-
clinical evaluation of potential therapeutic 
approaches to HIBM2. However, as no such model 
exists, clinical testing in advanced patients with 
products of sound scientiﬁ  c rationale with sup-
portive in vitro evidence of efﬁ  cacy along with in 
vivo demonstration of product safety, is justiﬁ  ed.
It has been documented that metabolic precur-
sors in serum can be taken up by cells in culture 
and converted to glycoconjugate-bound sialic acids 
(Oetke, Hinderlich et al. 2001; Hinderlich, Salama 
et al. 2004). In the data presented here, we dem-
onstrated that Lec3 cells grown in 2.5% serum had 
signiﬁ  cantly less sialic acid expression than cells 
grown in normal (10%) serum conditions. We were 
able to culture the cells in serum free media and 
obtain sialic acid levels close to 0.0 nmol/mg, but 
the cell morphology and growth characteristics 
were noticeably different from the original cells. 
Therefore, cells in 2.5% serum were used for sialic 
acid reconstitution assays, but the minimal amount 
of serum present may have prevented us from 
displaying differences between the wild type and 
M712T GNE forms more clearly.
The expression vector in this study utilizes the 
robust CMV promoter. This results in relatively high 
levels of GNE protein expression. Therefore, few 
copies of plasmid DNA are required to be transfected 
into a cell to obtain physiological effects. In addition, 
the wild type GNE enzyme will be subject to normal 
feedback regulation precluding overexpression of 
sialic acid. Although the vector will not integrate 
into the chromatin, extended expression is expected 
in muscle tissue because myocytes do not rapidly 
divide. One could also consider use of the sialuria 
variant of GNE for expression in HIBM patient´s 
cells to rescue the long-time hyposialylation of the 
tissue, of course taking into account the side effects 
of sialic acid overproduction observed in sialuria 
patients. We are currently validating a non immu-
nogenic muscle targeting delivery vehicle to deter-
mine the safety of the pUMVC3-GNE-wt vector in 
animals in preparation for clinical testing.
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Figure S1. Sequence alignment of GNE wt (NB8), M712T (MB18), and R266Q (R266Q). Original DNA sequence was con-
verted to protein to illustrate the amino acid mutations.
MEKNGNNRKLRVCVATCNRADYSKLAPIMFGIKTEPEFFELDVVVLGSH GNE #NP_005467
XXXXXXNRKLRVCVATCNRADYSKLAPIMFGIKTEPEFFELDVVVLGSH GNE NB8 seq
XXXXXXNRKLRVCVATCNRADYSKLAPIMFGIKTEPEFFELDVVVLGSH GNE MB18 seq
------NRKLRVCVATCNRADYSKLAPIMFGIKTEPEFFELDVVVLGSH GNE R266Q seq
LIDDYGNTYRMIEQDDFDINTRLHTIVRGEDEAAMVESVGLALVKLPDV GNE #NP_005467
LIDDYGNTYRMIEQDDFDINTRLHTIVRGEDEAAMVESVGLALVKLPDV GNE NB8 seq
LIDDYGNTYRMIEQDDFDINTRLHTIVRGEDEAAMVESVGLALVKLPDV GNE MB18 seq
LIDDYGNTYRMIEQDDFDINTRLHTIVRGEDEAAMVESVGLALVKLPDV GNE R266Q seq
LNRLKPDIMIVHGDRFDALALATSAALMNIRILHIEGGEVSGTIDDSIR GNE #NP_005467
LNRLKPDIMIVHGDRFDALALATSAALMNIRILHIEGGEVSGTIDDSIR GNE NB8 seq
LNRLKPDIMIVHGDRFDALALATSAALMNIRILHIEGGEVSGTIDDSIR GNE MB18 seq
LNRLKPDIMIVHGDRFDALALATSAALMNIRILHIEGGEVSGTIDDSIR GNE R266Q seq
HAITKLAHYHVCCTRSAEQHLISMCEDHDRILLAGCPSYDKLLSAKNKD GNE #NP_005467
HAITKLAHYHVCCTRSAEQHLISMCEDHDRILLAGCPSYDKLLSAKNKD GNE NB8 seq
HAITKLAHYHVCCTRSAEQHLISMCEDHDRILLAGCPSYDKLLSAKNKD GNE MB18 seq
HAITKLAHYHVCCTRSAEQHLISMCEDHDRILLAGCPSYDKLLSAKNKD GNE R266Q seq
YMSIIRMWLGDDVKSKDYIVALQHPVTTDIKHSIKMFELTLDALISFNK GNE #NP_005467
YMSIIRMWLGDDVKSKDYIVALQHPVTTDIKHSIKMFELTLDALISFNK GNE NB8 seq
YMSIIRMWLGDDVKSKDYIVALQHPVTTDIKHSIKMFELTLDALISFNK GNE MB18 seq
YMSIIRMWLGDDVKSKDYIVALQHPVTTDIKHSIKMFELTLDALISFNK GNE R266Q seq
RTLVLFPNIDAGSKEMVRVMRKKGIEHHPNFRAVKHVPFDQFIQLVAHA GNE #NP_005467
RTLVLFPNIDAGSKEMVRVMRKKGIEHHPNFRAVKHVPFDQFIQLVAHA GNE NB8 seq
RTLVLFPNIDAGSKEMVRVMRKKGIEHHPNFRAVKHVPFDQFIQLVAHA GNE MB18 seq
RTLVLFPNIDAGSKEMVRVMQ KKGIEHHPNFRAVKHVPFDQFIQLVAHA GNE R266Q seq
GCMIGNSSCGVREVGAFGTPVINLGTRQIGRETGENVLHVRDADTQDKI GNE #NP_005467
GCMIGNSSCGVREVGAFGTPVINLGTRQIGRETGENVLHVRDADTQDKI GNE NB8 seq
GCMIGNSSCGVREVGAFGTPVINLGTRQIGRETGENVLHVRDADTQDKI GNE MB18 seq
GCMIGNSSCGVREVGAFGTPVINLGTRQIGRETGENVLHVRDADTQDKI GNE R266Q seq
LQALHLQFGKQYPCSKIYGDGNAVPRILKFLKSIDLQEPLQKKFCFPPV GNE #NP_005467
LQALHLQFGKQYPCSKIYGDGNAVPRILKFLKSIDLQEPLQKKFCFPPV GNE NB8 seq
LQALHLQFGKQYPCSKIYGDGNAVPRILKFLKSIDLQEPLQKKFCFPPV GNE MB18 seq
LQALHLQFGKQYPCSKIYGDGNAVPRILKFLKSIDLQEPLQKKFCFPPV GNE R266Q seq
KENISQDIDHILETLSALAVDLGGTNLRVAIVSMKGEIVKKYTQFNPKT GNE #NP_005467
KENISQDIDHILETLSALAVDLGGTNLRVAIVSMKGEIVKKYTQFNPKT GNE NB8 seq
KENISQDIDHILETLSALAVDLGGTNLRVAIVSMKGEIVKKYTQFNPKT GNE MB18 seq
KENISQDIDHILETLSALAVDLGGTNLRVAIVSMKGEIVKKYTQFNPKT GNE R266Q seq
YEERINLILQMCVEAAAEAVKLNCRILGVGISTGGRVNPREGIVLHSTK GNE #NP_005467
YEERINLILQMCVEAAAEAVKLNCRILGVGISTGGRVNPREGIVLHSTK GNE NB8 seq
YEERINLILQMCVEAAAEAVKLNCRILGVGISTGGRVNPREGIVLHSTK GNE MB18 seq
YEERINLILQMCVEAAAEAVKLNCRILGVGISTGGRVNPREGIVLHSTK GNE R266Q seq
LIQEWNSVDLRTPLSDTLHLPVWVDNDGNCAALAERKFGQGKGLENFVT GNE #NP_005467
LIQEWNSVDLRTPLSDTLHLPVWVDNDGNCAALAERKFGQGKGLENFVT GNE NB8 seq
LIQEWNSVDLRTPLSDTLHLPVWVDNDGNCAALAERKFGQGKGLENFVT GNE MB18 seq
LIQEWNSVDLRTPLSDTLHLPVWVDNDGNCAALAERKFGQGKGLENFVT GNE R266Q seq
LITGTGIGGGIIHQHELIHGSSFCAAELGHLVVSLDGPDCSCGSHGCIE GNE #NP_005467
LITGTGIGGGIIHQHELIHGSSFCAAELGHLVVSLDGPDCSCGSHGCIE GNE NB8 seq
LITGTGIGGGIIHQHELIHGSSFCAAELGHLVVSLDGPDCSCGSHGCIE GNE MB18 seq
LITGTGIGGGIIHQHELIHGSSFCAAELGHLVVSLDGPDCSCGSHGCIE GNE R266Q seq
AYASGMALQREAKKLHDEDLLLVEGMSVPKDEAVGALHLIQAAKLGNAK GNE #NP_005467
AYASGMALQREAKKLHDEDLLLVEGMSVPKDEAVGALHLIQAAKLGNAK GNE NB8 seq
AYASGMALQREAKKLHDEDLLLVEGMSVPKDEAVGALHLIQAAKLGNAK GNE MB18 seq
AYASGMALQREAKKLHDEDLLLVEGMSVPKDEAVGALHLIQAAKLGNAK GNE R266Q seq
AQSILRTAGTALGLGVVNILHTMNPSLVILSGVLASHYIHIVKDVIRQQ GNE #NP_005467
AQSILRTAGTALGLGVVNILHTMNPSLVILSGVLASHYIHIVKDVIRQQ GNE NB8 seq
AQSILRTAGTALGLGVVNILHTMNPSLVILSGVLASHYIHIVKDVIRQQ GNE MB18 seq
AQSILRTAGTALGLGVVNILHTMNPSLVILSGVLASHYIHIVKDVIRQQ GNE R266Q seq
ALSSVQDVDVVVSDLVDPALLGAASMVLDYTTRRIY. GNE #NP_005467
ALSSVQDVDVVVSDLVDPALLGAASMVLDYTTRRIY.X GNE NB8 seq
ALSSVQDVDVVVSDLVDPALLGAAST VLDYTTRRIY.X GNE MB18 seq
ALSSVQDVDVVVSDLVDPALLGAASMVLDYTTRRIYHQ GNE R266Q seq